Table 1. Reactivity of IgM and IgG antibodies directed against JEV in ELISA and IIFT.

	anti-JEV IgM			anti-JEV IgG
	Sera positive by Panbio ELISA/sera tested [Panbio Units range]	Sera positive by InBios ELISA/sera tested [ISR range]	Sera positive by Euroimmun IIFT/sera tested [titre range]	Sera positive by InBios ELISA/sera tested [ISR range]	Sera positive by Euroimmun IIFT/sera tested [titre range]
PRNT50 positive vaccinees	50/78 (64%) [0.9–55]	56/78 (72%) [1.4–59.9]	51/78 (65%) [0–320]	6/91 (7%) [0.7–12.4]	91/97 (94%) [0–1000]
PRNT50 negative vaccinees	nd	nd	0/78 (0%)	nd	0/78 (0%)
anti-DENV positive patients	1/10 (10%)+ [2.0–21.3]	5/10 (50%) [3.5–17.8]	3/15 (20%)* [0–32]	17/20 (85%) [1.4–27.1]	20/20 (100%)* [10–1000]
German blood donors	nd	nd	4/200 (2%) [0–10]	nd	8/197 (4%) [0–32]

nd: not done.

ISR: InBios immune status ratio;

+: calculation of JE/dengue ratio can be used to determine the presumptive infection;

*incubation on Flavivirus Profile 2 can be used to determine the presumptive infection.